Microbot Medical Inc. · NASDAQ:MBOT
Microbot Medical — Investor Presentation (April 2025)
20 slides from Microbot Medical's investor presentation, Apr 30, 2025
Slide 1: Redefining Endovascular Robotics
microbot medical ad micrabot medical yo: a ; ENDOVASCULAR ROBOTIC SYSTEM iL Redefining Endovascular Robotics { | ibe Sty y
Slide 2: Safe Harbor Statement
Safe Harbor Statement This document (together with any oral statements made in connection with this document) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, relating t
Slide 3: Microbot At-a-Glance
Microbot At-a-Glance Large and Significant @ Differentiated First Mover Robotic Solution Advantage Emergent Market Unmet Needs + Many endovascular procedures are Many endov + Difficulty navigating complex LIBERTY® is the world’s 1* fully + No commercially available robotic HO tie Hint a) Ie anatomy
Slide 4: Large and Emergent Market
Large and Emergent Market @ >6 million annual endovascular procedures performed US Market Endovascular in the US (15 million worldwide) Procedures Performed Annually @ >$40B spent annually in the US Neurovascular Procedures @ Performed by 15,000 physicians — 9,000 interventional cardiologists — 3,00
Slide 5: Initial Target Market: Peripheral Vascular
Initial Target Market: Peripheral Vascular microbot INITIAL TARGET ANNUAL j TARGET PROCEDURES (USA): ; SPENDING(USA): PHYSICIANS (USA): 2.3M $15B 6,000 Peripheral Vascular . Procedures AVG. ANNUAL # OF : FACILITIES PERFORMING PROCEDURES PER g PROCEDURES (USA): PHYSICIAN (USA): 3 2,200 Hospitals ~400
Slide 6: Significant Unmet Needs
@ Significant Unmet Needs Endovascular procedures are ripe for disruptive innovation that can improve procedure effi HCP health & safety, while enabling access to quality care for both providers and patients Procedure Radiation Ergonomic Access Efficiency Risks Issues to Quality Care ® Managing cath
Slide 7: Clinical Outcomes from ACCESS-PVI Pivotal Study
Clinical Outcomes from ACCESS-PVI Pivotal Study microbot Robotic manipulation of guidewires and catheters with LIBERTY® was successful in all cases, minimizing radiation exposure and maintaining a desirable safety profile ' Participating Physicians Reported LIBERTY Performed as Planned with 92% Rela
Slide 8: Differentiated Robotic Solution
Differentiated Robotic Solution microbot The LIBERTY® Endovascular Robotic System is disruptive technology designed to change the standard of care for endovascular procedures Single-use, fully-disposable without need for capital investment Empowers physicians to precisely steer guidewires and cathet
Slide 9: Slide 9
Slide 10: Differentiated Robotic Solution: The LIBERTY Value Proposition
@ Differentiated Robotic Solution The LIBERTY® Value Proposition Improve Access to Robotics Improved Lower Improve Improve Increase Patient Access and Reduce Complexity Safety Costs Efficiency Care to Care UNMET NEED: Conventional | UNMET NEED: Due to UNMET NEED: Manual UNMET NEED: Wire UNMET NEED:
Slide 11: Differentiated Robotic Solution: Intellectual Property
@ Differentiated Robotic Solution micronpt LIBERTY® is protected by a strong intellectual property portfolio that includes patents and trademarks patent applications pending worldwide patents issued/allowed Worldwide trademarks ele registered © Worldwide ®
Slide 12: First Mover Advantage
First Mover Advantage microbot LIBERTY® was designed to eliminate barriers and enable adoption of robotics in endovascular procedures Barriers to Adoption Other Robotic Systems v Large capital investment with no v Disposable procedure kit v Annual service agreement Cost of acquisition Procedure set-
Slide 13: First Mover Advantage
@ First Mover Advantage There is currently no commercially robotic system available in the US for endovascular procedures ‘Several companies are developing robotic solutions due to the attractive market and untapped potential Microbot is uniquely positioned for success with our unique design and fir
Slide 14: Attractive Reimbursement
@ Attractive Reimbursement Targeted procedures have an attractive outpatient reimbursement with capacity to incorporate new technologies including LIBERTY® Y90 for Part 1 — Mapping procedure Dx Angiogram (75726) $43,990.21 Liver Cancer Part 2 —- Embolization procedure Coil placement (37242) Emboliza
Slide 15: Unique Business Model
@ Unique Business Model The fully disposable feature of LIBERTY® offers an attractive bu commercial success by reducing barriers for entry and increase operational efficiencies for all stakeholders No Maintenance Expense No Custom Infrastructure n LIBERTY® for Continuous Consumable Revenue ® No spec
Slide 16: Clear Path to Commercialization
© Clear Path to Commercialization microbet With the recent and successful completion of many major milestones, LIBERTY® has a clear path to U.S. launch in Q2 2025 cas Completed Received Submitted Clearance & IDE ISO 13486 Biocompatibility IDE 510(k) Commercialization Submission Cettification Tests A
Slide 17: Experienced Team
@ Experienced Team Leadership Team Harel Gadot CEO, President & Chairman Linkedin atm Earl Adamy Vice President of Strategic Marketing & Business Dev Linkedin 7m Eran Cohen Vice President of Global Integration Linkedin Simon Sharon Chief Technology Officer Linkedin Naama Moav Vice President of HR Li
Slide 18: Experienced Team: Board of Directors
@ Experienced Team Board of Directors a) -_ Harel Gadot Martin J. Madden Tal Wenderow Scott Burell, CPA CEO, President & Chairman Director Director Director LinkedIn Linkedin Linkedin LinkedIn ia a Aileen Stockburger P. Laxminarain David Wilson Director Director Director Linkedin Linkedin Linkedin
Slide 19: Summary
Summary microbot LIBERTY? is a differentiated solution in a large and emergent market, with clear unmet needs and attractive reimbursement In the U.S., endovascular procedures historically have high reimbursement, with capacity for integrating new technologies like robotics that is expected to add v
Slide 20: microbot medical
microbot medical ir@microbotmedical.com NASDAQ CM: MBOT liberty
Microbot Medical — Investor Presentation (April 2025) on 6ix